Similar Papers

Paper Title
Journal
Date
Author
Rituximab‐induced late onset neutropenia in newly‐diagnosed B‐cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism
Szu‐Chin Li ... Yi‐Chun Chen
American Journal of Hematology | VOL. 85
Szu‐Chin Li, et. al.Szu‐Chin Li ... Yi‐Chun Chen
08 Jul 2010
FcgRIIIa 158 V/F polymorphism predicts rituximab-induced late onset neutropenia in newly-diagnosed CD20-positive B-cell lymphoma but is not correlated with long-term survival: A prospective study at a single institution with long-term follow-up
Hung-Chih Lai ... Yu-Chieh Su
Tzu Chi Medical Journal | VOL. 25
Hung-Chih Lai, et. al.Hung-Chih Lai ... Yu-Chieh Su
18 Apr 2013
AB0614 Late-onset neutropenia after rituximab treatment in patients with ANCA-associated systemic vasculitis: a retrospective analysis of a register-based patient cohort
I Popov ... V Babak
Annals of the Rheumatic Diseases | VOL. 81
I Popov, et. al.I Popov ... V Babak
23 May 2022
Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms
Daniel Tesfa ... Jan Palmblad
Expert Review of Hematology | VOL. 4
Daniel Tesfa, et. al.Daniel Tesfa ... Jan Palmblad
01 Dec 2011
View more papers

More From: Multiple Sclerosis and Related Disorders

Paper Title
Journal
Date
Author
Progressive unilateral tremor associated with large confluent perirolandic juxtacortical lesions in multiple sclerosis
Samantha A Banks ... Eoin P Flanagan
Multiple Sclerosis and Related Disorders | VOL. -
Samantha A Banks, et. al.Samantha A Banks ... Eoin P Flanagan
01 Feb 2025
Effectiveness and safety of glucocorticoids bridging rituximab in neuromyelitis spectrum disorder
Chunyang Wang ... Chao Zhang
Multiple Sclerosis and Related Disorders | VOL. -
Chunyang Wang, et. al.Chunyang Wang ... Chao Zhang
01 Feb 2025
Cerebrospinal fluid biomarkers as predictors of multiple sclerosis severity.
Miguel Tolentino ... Anne H Cross
Multiple sclerosis and related disorders | VOL. 94
Miguel Tolentino, et. al.Miguel Tolentino ... Anne H Cross
01 Feb 2025
Effectiveness of 6-week dosing of Natalizumab versus continued 4-week treatment for Multiple Sclerosis: An observational registry-based study.
Raed Alroughani ... Samar F Ahmed
Multiple sclerosis and related disorders | VOL. 94
Raed Alroughani, et. al.Raed Alroughani ... Samar F Ahmed
01 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.